Michael Hofman
MBBS
Professor
👥Biography 个人简介
Michael Hofman at Peter MacCallum has been central to the development and clinical validation of PSMA-targeted theranostics in prostate cancer — both PSMA PET imaging for staging and response assessment, and lutetium-177-PSMA-617 (177Lu-PSMA-617) for treatment. He led the TheraP trial demonstrating superior outcomes with 177Lu-PSMA-617 versus cabazitaxel in metastatic CRPC, and his work contributed to the VISION trial leading to FDA approval of this treatment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Michael Hofman 的研究动态
Follow Michael Hofman's research updates
留下邮箱，当我们发布与 Michael Hofman（Peter MacCallum Cancer Centre）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment